Amylyx Pharmaceuticals (AMLX) Competitors $3.98 +0.16 (+4.19%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.98 0.00 (-0.13%) As of 04/17/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. CALT, AMPH, ADPT, ARDX, EVO, AUPH, BGM, OCUL, IOVA, and SNDXShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Adaptive Biotechnologies (ADPT), Ardelyx (ARDX), Evotec (EVO), Aurinia Pharmaceuticals (AUPH), Qilian International Holding Group (BGM), Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Adaptive Biotechnologies Ardelyx Evotec Aurinia Pharmaceuticals Qilian International Holding Group Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Amylyx Pharmaceuticals (NASDAQ:AMLX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts prefer AMLX or CALT? Amylyx Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 101.01%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Amylyx Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in AMLX or CALT? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is AMLX or CALT more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -36.97% -29.61% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the MarketBeat Community believe in AMLX or CALT? Amylyx Pharmaceuticals received 8 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 67.31% of users gave Amylyx Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes3567.31% Underperform Votes1732.69% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has more volatility & risk, AMLX or CALT? Amylyx Pharmaceuticals has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Which has preferable earnings & valuation, AMLX or CALT? Amylyx Pharmaceuticals has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M4.04$49.27M-$4.44-0.90Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media refer more to AMLX or CALT? In the previous week, Amylyx Pharmaceuticals had 7 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Amylyx Pharmaceuticals' average media sentiment score of 0.79 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Amylyx Pharmaceuticals Positive Calliditas Therapeutics AB (publ) Neutral SummaryAmylyx Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 15 of the 19 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$352.64M$6.44B$5.29B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-1.046.8821.7117.77Price / Sales4.04231.36379.3997.68Price / Cash5.5165.6738.2234.64Price / Book0.625.916.443.98Net Income$49.27M$142.72M$3.21B$247.44M7 Day Performance9.04%4.33%2.82%1.82%1 Month Performance9.34%-12.80%-8.66%-6.98%1 Year Performance101.01%-9.71%11.33%1.49% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.0834 of 5 stars$3.98+4.2%$8.00+101.0%+99.0%$352.64M$87.37M-1.04200Analyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.3733 of 5 stars$25.00-6.1%$43.50+74.0%-41.7%$1.19B$731.97M8.331,620Gap DownHigh Trading VolumeADPTAdaptive Biotechnologies3.8851 of 5 stars$7.71+3.2%$9.40+21.9%+200.4%$1.15B$178.96M-7.07790Positive NewsHigh Trading VolumeARDXArdelyx4.3459 of 5 stars$4.45-2.2%$10.61+138.5%-26.4%$1.06B$333.62M-27.8190Analyst RevisionNews CoverageGap UpEVOEvotec1.338 of 5 stars$2.97-2.9%$5.93+99.8%-50.3%$1.05B$777.05M0.004,200News CoverageGap UpAUPHAurinia Pharmaceuticals2.6059 of 5 stars$7.59-2.8%$11.50+51.5%+58.1%$1.04B$235.13M-50.60300News CoverageGap DownBGMQilian International Holding GroupN/A$10.62-0.9%N/AN/A$1.03B$25.10M0.00298Gap DownOCULOcular Therapeutix3.5766 of 5 stars$6.30-0.9%$16.38+159.9%-3.6%$1.00B$63.72M-4.77230Gap DownIOVAIovance Biotherapeutics4.2367 of 5 stars$3.03+1.0%$20.25+568.3%-74.1%$993.47M$164.07M-2.03500Analyst ForecastHigh Trading VolumeSNDXSyndax Pharmaceuticals3.3751 of 5 stars$11.01-2.1%$36.20+228.8%-44.5%$947.34M$23.68M-3.03110Gap Down Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Amphastar Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Ardelyx Competitors Evotec Competitors Aurinia Pharmaceuticals Competitors Qilian International Holding Group Competitors Ocular Therapeutix Competitors Iovance Biotherapeutics Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
